© 2003 Robert A. Freitas Jr. All Rights Reserved.

Robert A. Freitas Jr., Nanomedicine, Volume IIA: Biocompatibility, Landes Bioscience, Georgetown, TX, 2003

References 2200-2299

2200. T.A. Jennings, I. Peterson, C.A. Axiotis, G.E. Friedlaender, R.A. Cooke, J. Rosai, “Angiosarcoma associated with foreign body material. A report of three cases,” Cancer 62(1 December 1988):2436-2444.

2201. G. Lindeman, M.J. McKay, K.L. Taubman, A.M. Bilous, “Malignant fibrous histiocytoma developing in bone 44 years after shrapnel trauma,” Cancer 66(15 November 1990):2229-2232.

2202. M. Mhic Iomhair, S.M. Lavelle, “Effect of film size on production of foreign body sarcoma by perforated film implants,” Technol. Health Care 5(October 1997):331-334.

2203. J. Autian, A.R. Singh, J.E. Turner, G.W. Hung, L.J. Nunez, W.H. Lawrence, “Carcinogenesis from polyurethans,” Cancer Res. 35(June 1975):1591-1596.

2204. K. Stokes, K. Cobian, “Polyether polyurethanes for implantable pacemaker leads,” Biomaterials 3(October 1982):225-231.

2205. B.S. Oppenheimer, E.T. Oppenheimer, L. Danishefsky, A.P. Stout, F.R. Eirich, “Further studies of polymers as carcinogenic agents in animals,” Cancer Res. 15(1955):333-340.

2206. P. Alexander, E.S. Horning, “Observations on the Oppenheimer method of inducing tumours by subcutaneous implantation of plastic films,” in G.E.W. Wolstenholme, M. O’Connor, eds., Carcinogenesis: Mechanisms of Action, Ciba Foundation Symposium, Little, Brown, Boston, 1959, pp. 12-25.

2207. L. Weiss, “Some effects of mechanical trauma on the development of primary cancers and their metastases,” J. Forensic Sci. 35(May 1990):614-627.

2208. M. Rock, “Cancer,” in J. Black, G. Hastings, eds., Handbook of Biomaterial Properties, Chapman & Hall, London, 1998, pp. 529-544.

2209. J.J. Jacobs, A.K. Skipor, P.F. Doorn, P. Campbell, T.P. Schmalzreid, J. Black, H.C. Amstutz, “Cobalt and chromium concentrations in patients with metal on metal total hip replacements,” Clin. Orthop. 329(August 1996):S256-S263.

2210. W.J. Gillespie, C.M.A. Frampton, R.J. Henderson, P.M. Ryan, “The incidence of cancer following total hip replacement,” J. Bone Joint Surg. 70(August 1988):539-542; W.J. Gillespie, P. Doom, “Incidence of cancer after total hip replacement,” J. Bone Joint Surg. Br. 78(July 1996):680.

2211. T. Visuri, M. Koskenvuo, “Cancer risk after Mckee-Farrar total hip replacement,” Orthopedics 14(February 1991):137-142.

2212. P. Paavolainen, E. Pukkala, P. Pulkkinen, T. Visuri, “Cancer incidence after total knee arthroplasty: a nationwide Finnish cohort from 1980 to 1996 involving 9,444 patients,” Acta Orthop. Scand. 70(December 1999):609-617.

2213. O. Nyren, J.K. McLaughlin, G. Gridley, A. Ekbom, O. Johnell, J.F. Fraumeni Jr., H.O. Adami, “Cancer risk after hip replacement with metal implants: a population-based cohort study in Sweden,” J. Natl. Cancer Inst. 87(4 January 1995):28-33.

2214. E.B. Mathiesen, A. Ahlbom, G. Bermann, J.U. Lindgren, “Total hip replacement and cancer. A cohort study,” J. Bone Joint Surg. Br. 77(May 1995):345-350.

2215. T. Visuri, E. Pukkala, P. Paavolainen, P. Pulkkinen, E.B. Riska, “Cancer risk after metal on metal and polyethylene on metal total hip arthroplasty,” Clin. Orthop. 329(August 1996):S280-S289 (Suppl).

2216. P. Paavolainen, E. Pukkala, P. Pulkkinen, T. Visuri, “Cancer incidence in Finnish hip replacement patients from 1980 to 1995: a nationwide cohort study involving 31,651 patients,” J. Arthroplasty 14(April 1999):272-280; 15(January 2000):136-137 (erratum).

2217. H. Berkel, D.C. Birdsell, H. Jenkins, “Breast augmentation: a risk factor for breast cancer?” N. Engl. J. Med. 326(18 June 1992):1649-1653.

2218. K.G. Brand, in L.R. Rubin,, ed., Biomaterials in Reconstructive Surgery, C.V. Mosby, St. Louis, MO, 1983, pp. 36-; K.G. Brand, “Do implanted medical devices cause cancer?” J. Biomater. Appl. 8(April 1994):325-343.

2219. K.H. Kjoller, C. Krag, S. Friis, “Silicone breast implants and breast cancer,” Ugeskr. Laeger. 159(17 March 1997):1744-1748. In Danish.

2220. Mearl F. Stanton, M. Layard, A. Tegeris, E. Miller, M. May, E. Morgan, A. Smith, “Relation of Particle Dimension to Carcinogenicity in Amphibole Asbestoses and Other Fibrous Minerals,” J. Natl. Cancer Inst. 67(November 1981):965-975; Mearl F. Stanton, M. Layard, A. Tegeris, E. Miller, M. May, E. Kent, “Carcinogenicity of fibrous glass: pleural response in the rat in relation to fiber dimension,” J. Natl. Cancer Inst. 58(March 1977):587-603.

2221. J.S. Harington, “The carcinogenicity of chrysotile asbestos,” Ann. N.Y. Acad. Sci. 643(31 December 1991):465-472.

2222. T.K. Hei, C.O. Piao, Z.Y. He, D. Vannais, C.A. Waldren, “Chrysotile is a strong mutagen in mammalian cells,” Cancer Res. 52(15 November 1992):6305-6309.

2223. P.J. Landrigan, W.J. Nicholson, Y. Suzuki, J. Ladou, “The hazards of chrysotile asbestos: a critical review,” Ind. Health 37(July 1999):271-280.

2224. U.S. Department of Health and Human Services, Seventh Annual Report on Carcinogens, DHHS Pub. No. (PHS) PB85-134633, NTIS, Springfield, VA, 1994.

2225. J.C. Barrett, P.W. Lamb, R.W. Wiseman, “Multiple mechanisms for the carcinogenic effects of asbestos and other mineral fibers,” Environ. Health Perspect. 81(May 1989):81-89.

2226. T.W. Hesterberg, J.C. Barrett, “Dependence of asbestos- and mineral dust-induced transformation of mammalian cells in culture on fiber dimension,” Cancer Res. 44(May 1984):2170-2180.

2227. L.E. Lipkin, “Cellular effects of asbestos and other fibers: correlations with in vivo induction of pleural sarcoma,” Environ. Health Perspect. 34(February 1980):91-102.

2228. A. Churg, B. Wiggs, “Fiber size and number in amphibole asbestos-induced mesothelioma,” Am. J. Pathol. 115(June 1984):437-442.

2229. L. Bonneau, C. Malard, H. Pezerat, “Studies on surface properties of asbestos. II. Role of dimensional characteristics and surface properties of mineral fibers in the induction of pleural tumors,” Environ. Res. 41(October 1986):268-275.

2230. Y. Murai, M. Kitagawa, K. Matsui, F. Koizumi, A. Miwa, “Asbestos fiber analysis in nine lung cancer cases with high asbestos exposure,” Arch. Environ. Health 50(July-August 1995):320-325.

2231. W. Malorni, F. Iosi, M. Falchi, G. Donelli, “On the mechanism of cell internalization of chrysotile fibers: an immunocytochemical and ultrastructural study,” Environ. Res. 52(August 1990):164-177.

2232. M.C. Jaurand, “Mechanisms of fiber-induced genotoxicity,” Environ. Health Perspect. 105(September 1997):1073-1084 (Suppl).

2233. E. Dopp, D. Schiffmann, “Analysis of chromosomal alterations induced by asbestos and ceramic fibers,” Toxicol. Lett. 96-97(August 1998):155-162.

2234. T.K. Hei, Z.Y. He, K. Suzuki, “Effects of antioxidants on fiber mutagenesis,” Carcinogenesis 16(July 1995):1573-1578.

2235. J.S. Hanas, C.G. Gunn, “Inhibition of transcription factor IIIA-DNA interactions by xenobiotic metal ions,” Nucleic Acids Res. 24(1 March 1996):924-930.

2236. A. Leonard, G.B. Gerber, “Mutagenicity, carcinogenicity and teratogenicity of aluminum,” Mutat. Res. 196(November 1988):247-257.

2237. B. Epe, “Genotoxicity of singlet oxygen,” Chem. Biol. Interact. 80(1991):239-260.

2238. D.L. Woodland, M.A. Blackman, “How do T-cell receptors, MHC molecules and superantigens get together?” Immunol. Today 14(May 1993):208-212.

2239. S. Surman, A.M. Deckhut, M.A. Blackman, D.L. Woodland, “MHC-specific recognition of a bacterial superantigen by weakly reactive T cells,” J. Immunol. 152(15 May 1994):4893-4902.

2240. A.M. Deckhut, Y. Chien, M.A. Blackman, D.L. Woodland, “Evidence for a functional interaction between the beta chain of major histocompatibility complex class II and the T cell receptor alpha chain during recognition of a bacterial superantigen,” J. Exp. Med. 180(1 November 1994):1931-1935.

2241. D.L. Woodland, R. Wen, M.A. Blackman, “Why do superantigens care about peptides?” Immunol. Today 18(January 1997):18-22.

2242. R. Wen, D.R. Broussard, S. Surman, T.L. Hogg, M.A. Blackman, D.L. Woodland, “Carboxy-terminal residues of major histocompatibility complex class II-associated peptides control the presentation of the bacterial superantigen toxic shock syndrome toxin-1 to T cells,” Eur. J. Immunol. 27(March 1997):772-781.

2243. R. Wen, S. Surman, M.A. Blackman, D.L. Woodland, “The conventional CD4+ T cell response to staphylococcal enterotoxin B is modified by its superantigenic activity,” Cell Immunol. 176(15 March 1997):166-172.

2244. P.C. Doherty, R.A. Tripp, A.M. Hamilton-Easton, R.D. Cardin, D.L. Woodland, M.A. Blackman, “Tuning into immunological dissonance: an experimental model for infectious mononucleosis,” Curr. Opin. Immunol. 9(August 1997):477-483.

2245. R.G. Ulrich, “Evolving superantigens of Staphylococcus aureus,” FEMS Immunol. Med. Microbiol. 27(January 2000):1-7.

2246. S. Macphail, “Superantigens: mechanisms by which they may induce, exacerbate and control autoimmune diseases,” Int. Rev. Immunol. 18(1999):141-180.

2247. Nadrian C. Seeman, “Nucleic acid junctions and lattices,” J. Theor. Biol. 99(1982):237-247; Nadrian C. Seeman et al, “New Motifs in DNA Nanotechnology,” Nanotechnology 9(September 1998):257-273. See also: http://seemanlab4.chem.nyu.edu/nanobib.html

2248. S. Schmidt-Acevedo, B. Perez-Romano, A. Ruiz-Arguelles, “LE cells result from phagocytosis of apoptotic bodies induced by antinuclear antibodies,” J. Autoimmun. 15(August 2000):15-20.

2249. T. Trangas, N. Courtis, G.A. Pangalis, H.V. Cosmides, C. Ioannides, M. Papamichail, C.M. Tsiapalis, “Polyadenylic acid polymerase activity in normal and leukemic human leukocytes,” Cancer Res. 44(September 1984):3691-3697.

2250. A.G. Baranovsky, V.G. Matushin, A.V. Vlassov, V.G. Zabara, V.A. Naumov, R. Giege, V.N. Buneva, G.A. Nevinsky, “DNA- and RNA-hydrolyzing antibodies from the blood of patients with various forms of viral hepatitis,” Biochemistry (Moscow) 62(December 1997):1358-1366.

2251. V.N. Buneva, T.G. Kanyshkova, A.V. Vlassov, D.V. Semenov, D.Yu. Khlimankov, L.R. Breusova, G.A. Nevinsky, “Catalytic DNA- and RNA-hydrolyzing antibodies from milk of healthy human mothers,” Appl. Biochem. Biotechnol. 75(October 1998):63-76.

2252. M.A. Surzhik, A.E. Duks, N.G. Diatlova, E.A. Glazunov, G.Ia. Feldmane, A.L. Timkovskii, “Interrelationship between the chain length of poly-L-lysine and the degree of protection of polyribonucleotide interferon inducers from human blood nucleases,” Antibiot. Khimioter. 38(July 1993):21-25. In Russian.

2253. M. Maier, K. Bleicher, H. Kalthoff, E. Bayer, “Enzymatic degradation of various antisense oligonucleotides: monitoring and fragment identification by MECC and ES-MS,” Biomed. Pept. Proteins Nucleic Acids 1(1995):235-242.

2254. P.S. Eder, R.J. DeVine, J.M. Dagle, J.A. Walder, “Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3’ exonuclease in plasma,” Antisense Res. Dev. 1(Summer 1991):141-151.

2255. A. Peyman, E. Uhlmann, “Minimally modified oligonucleotides – combination of end-capping and pyrimidine-protection,” Biol. Chem. Hoppe Seyler 377(January 1996):67-70.

2256. E. Uhlmann, A. Ryte, A. Peyman, “Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation,” Antisense Nucleic Acid Drug Dev. 7(August 1997):345-350.

2257. D. Pandolfi, F. Rauzi, M.L. Capobianco, “Evaluation of different types of end-capping modifications on the stability of oligonucleotides toward 3’- and 5’-exonucleases,” Nucleosides Nucleotides 18(September 1999):2051-2069.

2258. D. Pisetsky, D. Drayton, Z.Q. Wu, “Specificity of antibodies to bacterial DNA in the sera of healthy human subjects and patients with systemic lupus erythematosus,” J. Rheumatol. 26(September 1999):1934-1938.

2259. A.V. Kozyr et al, “Autoantibodies to nuclear antigens: correlation between cytotoxicity and DNA-hydrolyzing activity,” Appl. Biochem. Biotechnol. 83(January-March 2000):255-268; 268-269, 297-313 (discussion).

2260. D.S. Pisetsky, “Specificity and immunochemical properties of antibodies to bacterial DNA,” Methods 11(January 1997):55-61.

2261. H. Sano, O. Takai, N. Harata, K. Yoshinaga, I. Kodama-Kamada, T. Sasaki, “Binding properties of human anti-DNA antibodies to cloned human DNA fragments,” Scand. J. Immunol. 30(July 1989):51-63.

2262. J. Ara, R. Ali, “Polynucleotide specificity of anti-reactive oxygen species (ROS) DNA antibodies,” Clin. Exp. Immunol. 94(October 1993):134-139.

2263. D.S. Pisetsky, C.F. Reich, “The influence of DNA size on the binding of anti-DNA antibodies in the solid and fluid phase,” Clin. Immunol. Immunopathol. 72(September 1994):350-356.

2264. D.S. Pisetsky, T.C. Gonzalez, “The influence of DNA size on the binding of antibodies to DNA in the sera of normal human subjects and patients with systemic lupus erythematosus,” Clin. Exp. Immunol. 116(May 1999):354-359.

2265. E.M. Lafer, A. Moller, A. Nordheim, B.D. Stollar, A. Rich, “Antibodies specific for left-handed Z-DNA,” Proc. Natl. Acad. Sci. (USA) 78(June 1981):3546-3550.

2266. A. Moller, J.E. Gabriels, E.M. Lafer, A. Nordheim, A. Rich, B.D. Stollar, “Monoclonal antibodies recognize different parts of Z-DNA,” J. Biol. Chem. 257(25 October 1982):12081-12085.

2267. T.J. Thomas, N.L. Meryhew, R.P. Messner, “DNA sequence and conformation specificity of lupus autoantibodies. Preferential binding to the left-handed Z-DNA form of synthetic polynucleotides,” Arthritis Rheum. 31(March 1988):367-377.

2268. V. Sehgal, R. Ali, “Naturally occurring anti-native DNA antibodies in SLE binding Z-DNA,” Indian J. Med. Res. 92(June 1990):158-162.

2269. K. Alam, R. Ali, “Human autoantibody binding to multiple conformations of DNA,” Biochem. Int. 26(March 1992):597-605.

2270. R. Haworth, A.M. Pilling, “The PCR assay in the preclinical safety evaluation of nucleic acid medicines,” Hum. Exp. Toxicol. 19(May 2000):267-276.

2271. E.A. Snezhkova et al, “DNA-coated carbon adsorbents experimental assessment and results of severe psoriasis treatment,” Biomater. Artif. Cells Immobilization Biotechnol. 20(1992):1201-1221.

2272. E.R. Kandimalla, D.R. Shaw, S. Agrawal, “Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotide on human complement and coagulation,” Bioorg. Med. Chem. Lett. 8(18 August 1998):2103-2108.

2273. D.R. Shaw, P.K. Rustagi, E.R. Kandimalla, A.N. Manning, Z. Jiang, S. Agrawal, “Effect of synthetic oligonucleotides on human complement and coagulation,” Biochem. Pharmacol. 53(25 April 1997):1123-1132.

2274. J.F. Albright, R.A. Goldstein, “Airborne pollutants and the immune system,” Otolaryngol. Head Neck Surg. 114(February 1996):232-238.

2275. M. Garcia Mesa, A. Casaco Parada, L. Arruzazabala Valmana, R. Gonzalez Alvarez, A. Rodriguez de la Vega, “Role of chemical mediators in bronchoconstriction induced by kerosene,” Allergol. Immunopathol. (Madrid) 16(November-December 1988):421-423.

2276. M.R. Hurle, M. Gross, “Protein engineering techniques for antibody humanization,” Curr. Opin. Biotechnol. 5(August 1994):428-433.

2277. C. Klingbeil, D.H. Hsu, “Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use,” Toxicol. Pathol. 27(January-February 1999):1-3.

2278. V. Morea, A.M. Lesk, A. Tramontano, “Antibody modeling: implications for engineering and design,” Methods 20(March 2000):267-279.

2279. Gang He, Martin H. Muser, Mark O. Robbins, “Adsorbed Layers and the Origin of Static Friction,” Science 284(4 June 1999):1650-1652.

2280. Jim Scheppele, “Surface Modification of Plastics for Medical Device Applications”; http://www.a2c2.com/archive/699surfacemod.htm

2281. Advanced Surface Technology, Inc., http://www.astp.com/coating/advanced_frame.html or http://64.77.49.201/index.cfm; MetroLine Industries, Inc., “Biocompatibility,” http://www.metrolineindustries.com/01surfmodapps/05biocompatibility/index.html; Spire Corporation, Medical Division (Spire Biomedical), http://www.spirebiomedical.com/index.html; SurModics Inc., http://www.surmodics.com/about.html; Ultramet, http://www.ultramet.com; Vitek Research Corp., http://www.vitekres.com/Biomedical.htm and http://www.vitekres.com/Coatings_Substrates.html.

2282. L. Gettleman, “Noble alloys in dentistry,” Curr. Opin. Dent. 1(April 1991):218-221.

2283. S. Canay, M. Oktemer, “In vitro corrosion behavior of 13 prosthodontic alloys,” Quintessence 23(April 1992):279-287.

2284. C.H. Chouard, P. Pialoux, “Biocompatibility of cochlear implants,” Bull. Acad. Natl. Med. 179(March 1995):549-555. In French.

2285. G. Kansu, A.K. Aydin, “Evaluation of the biocompatibility of various dental alloys: Part 2 – Toxic potentials,” Eur. J. Prosthodont. Restor. Dent. 4(September 1996):129-136; “Evaluation of the biocompatibility of various dental alloys: Part 2 – Allergenical potentials,” Eur. J. Prosthodont. Restor. Dent. 4(December 1996):155-161.

2286. D. Williams, “Tis virtue not birth that makes us noble: the role of noble metals in medical devices,” Med. Device Technol. 7(October 1996):7-11.

2287. S. Schmidt, K. Horch, R. Normann, “Biocompatibility of silicon-based electrode arrays implanted in feline cortical tissue,” J. Biomed. Mater. Res. 27(November 1993):1393-1399.

2288. A. Maureen Rouhi, “Nanotechnology – from the ACS meeting,” C&EN (20 April 1998):57-62.

2289. I.Y. Galaev, B. Mattiasson, “Smart polymers and what they could do in biotechnology and medicine,” Trends Biotechnol. 17(August 1999):335-340.

2290. Mike Meredith, Florida State University, Neuroscience Program, “Why do we sneeze?” National Science and Technology Week 1997; http://www.nsf.gov/nstw_questions/biol/quest272.htm

2291. W.M. Price, H.L. Batsel, “Respiratory neurons participating in sneeze and in response to resistance to expiration,” Exp. Neurol. 29(December 1970):554-570.

2292. F. Wallois, J.M. Macron, V. Jounieaux, B. Duron, “Trigeminal afferences implied in the triggering or inhibition of sneezing in cats,” Neurosci. Lett. 122(28 January 1991):145-147.

2293. F. Wallois, F. Gros, M. Condamin, J.M. Macron, “Postnatal development of the anterior ethmoidal nerve in cats: unmyelinated and myelinated nerve fiber analysis,” Neurosci. Lett. 160(1 October 1993):221-224.

2294. P.A. Greenberger, “Nasal receptors and reflexes,” Allergy Asthma Proc. 19(July-August 1998):175-179.

2295. J.G. Widdicombe, “Pulmonary and respiratory tract receptors,” J. Exp. Biol. 100(October 1982):41-57.

2296. T. Nishino, “Physiological and pathophysiological implications of upper airway reflexes in humans,” Jpn. J. Physiol. 50(February 2000):3-14.

2297. Mark Hersch, “Loss of ability to sneeze in lateral medullary syndrome,” Neurology 54(25 January 2000):520-521.

2298. S. Co, “Intractable sneezing: case report and literature review,” Arch. Neurol. 36(February 1979):111-112.

2299. Robert West, “Why does plucking my eyebrows make me sneeze?” 5 Aug 1997; http://www.madsci.org/posts/archives/aug97/870807554.Me.r.html

Last updated on 16 April 2004